Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin

Acta Diabetologica

Volumn 49, Issue 3, 2012, Pages 225-230

  Aoki, Kazutaka ^a,b   Kamiyama, Hiroshi ^a,b   Yoshimura, Kouichiro ^b   Shibuya, Makoto ^a,b   Masuda, Kiyomi ^a   Terauchi, Yasuo ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOSUKA KYOSAI HOSPITAL   (Japan)

Author keywords

glucosidase inhibitor; Drug adherence; GIP; GLP 1; Miglitol

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; MIGLITOL; SITAGLIPTIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; MALE; MEAL; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

1-DEOXYNOJIRIMYCIN; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOOD-DRUG INTERACTIONS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PYRAZINES; TRIAZOLES;

EID: 84862756200     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-011-0322-9     Document Type: Article

References (31)

1. Macfarlane DP, Paterson KR, Fisher M (2007) Oral anti diabetic agents as cardiovascular drugs. Diabetes Obes Metab 9:23-30 (Pubitemid 44921038)
2. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, Magid DJ (2006) Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 166:1836-1841 (Pubitemid 44455165)
3. Hertz RP, Unger AN, Lustik MB (2005) Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther 27:1064-1073 (Pubitemid 41262464)
4. Nemoto M, Tajima N, Kawamori R (2011) Efficacy of combined use of miglitol in type 2 diabetes patients receiving insulin therapy-placebo- controlled double-blind comparative study. Acta Diabetol 48:15-20
5. Hsieh SH, Shih KC, Chou CW, Chu CH (2011) Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas. Acta Diabetol 48:71-77
6. Nathan DM, Buse JB, Davidson MB (2006) Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29:1963-1972 (Pubitemid 44156663)
7. Aoki K, Kato H, Terauchi Y (2007) Divided-dose administration of miglitol just before and 15 min after the start of a meal smoothes postprandial plasma glucose excursions and serum insulin responses in healthy men. Endocr J 54:1009-1014 (Pubitemid 351346787)
8. Aoki K, Nakamura A, Ito S, Nezu U, Iwasaki T, Takahasi M, Kimura M, Terauchi Y (2007) Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients. Diabetes Res Clin Pract 78:30-33 (Pubitemid 47348162)
9. Aoki K, Nakajima S, Nezu U, Shinoda K, Terauchi Y (2008) Comparison of pre- versus postmeal administration of miglitol for 3 months in type 2 diabetic patients. Diabetes Obes Metab 10:970-972
10. Aoki K, Muraoka T, Ito Y, Togashi Y, Terauchi Y (2010) Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: a crossover study. Intern Med 49:1085-1087
11. Narita T, Katsuura Y, Sato T, Hosoba M, Fujita H, Morii T, Yamada Y (2009) Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese type 2 diabetic patients. Diabet Med 26:187-188
12. Arakawa M, Ebato C, Mita T, Fujitani Y, Shimizu T, Watada H, Kawamori R, Hirose T (2008) Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism 57:1299-1306
13. Lee A, Patrick P, Wishart J, Horowitz M, Morley JE (2002) The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 4:329-335 (Pubitemid 34947095)
14. Aoki K, Miyazaki T, Nagakura J, Orime K, Togashi Y, Terauchi Y (2010) Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucose dependent insulinotropic polypeptide levels in healthy men. Endocr J 57:673-677
15. Fadini GP, de Kreutzenberg SV, Gjini R, Avogaro A (2011) The metabolic syndrome influences the response to incretin-based therapies. Acta Diabetol [Epub ahead of print]
16. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P et al (2006) Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91:4612-4619 (Pubitemid 44833446)
17. Aoki K, Masuda K, Miyazaki T, Togashi Y, Terauchi Y (2010) Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocr J 57:667-672
18. Masuda K, Aoki K, Terauchi Y (2011) Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance (NGT), impaired fasting glucose (IFG) or impaired glucose tolerance (IGT). J Diabetes Invest, (in press) doi:10.1111/j.2040-1124.2011.00129.x
19. The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus (2010) Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 1:212-228
20. Moritoh Y, Takeuchi K, Hazama M (2010) Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta- cells in prediabetic db/db mice. Diabetes Obes Metab 12:224-233
21. Migoya EM, Bergeron R, Miller JL, Snyder RN, Tanen M, Hilliard D et al (2010) Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 88:801-808
22. Terauchi Y, Takamoto I, Kubota N, Matsui J, Suzuki R, Komeda K et al (2007) Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 117:246-257 (Pubitemid 46048470)
23. Kadowaki T, Miyake Y, Hagura R, Akanuma Y, Kajinuma H, Kuzuya N, Takaku F, Kosaka K (1984) Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 26:44-49 (Pubitemid 14182349)
24. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R (2003) Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144:5149-5158 (Pubitemid 37476040)
25. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME, NN8022-1807 Study Group (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374:1606-1616
26. Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, TrautmannM(2010) Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 33:1173-1175
27. Uttenthal LO, Ukponmwan OO, Wood SM, Ghiglione M, Ghatei MA, Trayner IM, Bloom SR (1986) Long-term effects of intestinal alpha-glucosidase inhibition on postprandial glucose, pancreatic and gut hormone responses and fasting serum lipids in diabetics on sulphonylureas. Diabet Med 3:155-160 (Pubitemid 16144611)
28. Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA (1998) Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in type 2 diabetic patients. Diabet Med 15:485-491
29. Hücking K, Kostic Z, Pox C, Ritzel R, Holst JJ, Schmiegel W, Nauck MA (2005) Alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in type 2 diabetic patients. Diabet Med 22:470-476 (Pubitemid 40516249)
30. Seino Y, Fukushima M, Yabe D (2010) GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Invest 1:8-23
31. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H et al (2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8:738-742 (Pubitemid 34778728)